RecruitingNCT06043232

MMR/MSI Phenotypes in Prediction of Tumor Vaccine Benefit for Gliomas

The Role and Mechanism of MMR/MSI Phenotypes in Evaluating Vaccine Benefit in Glioblastoma

Sponsor

Huashan Hospital

Enrollment

360 participants

Start Date

Sep 1, 2023

Study Type

OBSERVATIONAL

Conditions

Glioma

Summary

Glioblastoma (GBM) is the most malignant primary intracranial tumor with a median survival of about 18 months, and new therapies are urgently needed. Tumor vaccines has been shown to improve survival of GBM, but not all patients can benefit from vaccine treatment and biomarkers are urgently needed. Deletion of mismatch repair (MMR) protein and microsatellite instability (MSI) state are important features in the biological evolution of GBM, and may be used as markers for tumor vaccine. Therefore, this project will collect samples from GBM patients before and after vaccine treatment respectively, and evaluate the role of MMR/MSI gene phenotype in predicting vaccine efficacy and the potential molecular mechanism. Moreover, MMR/MSI phenotypes will be assessed by deep-learning and radiomics using images to establish noninvasive markers for vaccine.

Eligibility

Min Age: 18 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at whether certain genetic features of brain tumors (called gliomas) can predict which patients might benefit from a personalized tumor vaccine. Researchers will analyze tumor tissue removed during surgery to understand how the immune system interacts with different types of gliomas. **You may be eligible if...** - You are between 18 and 80 years old - You have been diagnosed with a glioma (a type of brain tumor) - You are having surgery at Huashan Hospital (Fudan University) and enough tumor tissue can be collected during the operation without affecting your standard care **You may NOT be eligible if...** - You are currently enrolled in another clinical trial - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.